Maria AntÃ²nia Busquets

List of Publications by Year
in descending order

64 papers	2,214 citations	331670 21 h-index	223800 46 g-index
64 all docs	64 docs citations	64 times ranked	4046 citing authors

#	Article	IF	Citations
1	Activity of Antibiotics and Potential Antibiofilm Agents against Biofilm-Producing Mycobacterium avium-intracellulare Complex Causing Chronic Pulmonary Infections. Antibiotics, 2022, 11, 589.	3.7	3
2	Prussian Blue: A Safe Pigment with Zeolitic-Like Activity. International Journal of Molecular Sciences, 2021, 22, 780.	4.1	29
3	Prussian Blue: A Nanozyme with Versatile Catalytic Properties. International Journal of Molecular Sciences, 2021, 22, 5993.	4.1	52
4	Synthesis and validation of DOPY: A new gemini dioleylbispyridinium based amphiphile for nucleic acid transfection. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 279-292.	4.3	7
5	Dual Effect of Prussian Blue Nanoparticles on AÎ²40 Aggregation: Î²-Sheet Fibril Reduction and Copper Dyshomeostasis Regulation. Biomacromolecules, 2021, 22, 430-440.	5.4	11
6	Superparamagnetic Nanoparticles with Efficient Near-Infrared Photothermal Effect at the Second Biological Window. Molecules, 2020, 25, 5315.	3.8	7
7	Dual Behavior of Long-Chain Fatty Acids and Their Cyclooxygenase/Lipoxygenase Metabolites on Human Intestinal Caco-2 Cell Growth. Frontiers in Pharmacology, 2020, 11, 529976.	3.5	11
8	Prussian blue nanoparticles: synthesis, surface modification, and biomedical applications. Drug Discovery Today, 2020, 25, 1431-1443.	6.4	80
9	Flash tooth whitening: A friendly formulation based on a nanoencapsulated reductant. Colloids and Surfaces B: Biointerfaces, 2020, 195, 111241.	5.0	7
10	Facile Synthesis of Novel Prussian Blueâ€“Lipid Nanocomplexes. Molecules, 2019, 24, 4137.	3.8	10
11	Dual responsive gelatin-based nanoparticles for enhanced 5-fluorouracil efficiency. Colloids and Surfaces B: Biointerfaces, 2018, 172, 646-654.	5.0	23
12	Iron Oxide Nanoparticles in Photothermal Therapy. Molecules, 2018, 23, 1567.	3.8	222
13	Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs. Journal of Natural Products, 2017, 80, 278-289.	3.0	68
14	Effect of PEGylation on Ligand-Targeted Magnetoliposomes: A Missed Goal. ACS Omega, 2017, 2, 6544-6555.	3.5	12
15	Magnetic Nanoemulsions: Comparison between Nanoemulsions Formed by Ultrasonication and by Spontaneous Emulsification. Nanomaterials, 2017, 7, 190.	4.1	30
16	Evidence of Protein Adsorption in Pegylated Liposomes: Influence of Liposomal Decoration. Nanomaterials, 2017, 7, 37.	4.1	19
17	Key Points Concerning Amyloid Infectivity and Prion-Like Neuronal Invasion. Frontiers in Molecular Neuroscience, 2016, 9, 29.	2.9	19
18	Liposomes Loaded with Hydrophobic Iron Oxide Nanoparticles: Suitable T2 Contrast Agents for MRI. International Journal of Molecular Sciences, 2016, 17, 1209.	4.1	47

#	Article	IF	Citations
19	Oil-in-water nanoemulsions are suitable for carrying hydrophobic compounds: Indomethacin as a model of anti-inflammatory drug. International Journal of Pharmaceutics, 2016, 515, 749-756.	5.2	24
20	Kinetics characterization of c-Src binding to lipid membranes: Switching from labile to persistent binding. Colloids and Surfaces B: Biointerfaces, 2016, 138, 17-25.	5.0	19
21	Amyloids in solid-state nuclear magnetic resonance: potential causes of the usually low resolution. International Journal of Nanomedicine, 2015, 10, 6975.	6.7	5
22	Magnetic Nanoparticles Cross the Blood-Brain Barrier: When Physics Rises to a Challenge. Nanomaterials, 2015, 5, 2231-2248.	4.1	67
23	CouldÎ±-Synuclein Amyloid-Like Aggregates Trigger a Prionic Neuronal Invasion?. BioMed Research International, 2015, 2015, 1-7.	1.9	10
24	Immunoliposome-mediated drug delivery to Plasmodium -infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial strategy. Journal of Controlled Release, 2015, 210, 217-229.	9.9	73
25	Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. International Journal of Nanomedicine, 2015, 10, 1727.	6.7	378
26	Iron Oxide Nanoparticles for Magnetically-Guided and Magnetically-Responsive Drug Delivery. International Journal of Molecular Sciences, 2015, 16, 8070-8101.	4.1	367
27	Predicting the aggregation propensity of prion sequences. Virus Research, 2015, 207, 127-135.	2.2	7
28	Interaction of two overlapped synthetic peptides from GB virus C with charged mono and bilayers. Colloids and Surfaces B: Biointerfaces, 2013, 105, 7-13.	5.0	2
29	Physicochemical characterization of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide: Interaction with model membranes. International Journal of Pharmaceutics, 2012, 436, 593-601.	5.2	7
30	Phospholipid Bilayer-Perturbing Properties Underlying Lysis Induced by pH-Sensitive Cationic Lysine-Based Surfactants in Biomembranes. Langmuir, 2012, 28, 11687-11698.	3.5	17
31	Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 1567-1573.	2.6	14
32	Effect of E1(64â€“81) hepatitis G peptide on the in vitro interaction of HIV-1 fusion peptide with membrane models. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 2178-2188.	2.6	17
33	Biophysical Investigations of GBVâ€C E1 Peptides as Potential Inhibitors of HIVâ€1 Fusion Peptide. ChemPhysChem, 2011, 12, 2816-2822.	2.1	12
34	Analysis of HIV-1 fusion peptide inhibition by synthetic peptides from E1 protein of GB virus C. Journal of Colloid and Interface Science, 2011, 360, 124-131.	9.4	22
35	Time-Lapse Atomic Force Microscopy Observations of the Morphology, Growth Rate, and Spontaneous Alignment of Nanofibers Containing a Peptide-Amphiphile from the Hepatitis G Virus (NS3 Protein). Journal of Physical Chemistry B, 2010, 114, 620-625.	2.6	5
36	A Langmuir Monolayer Study of the Interaction of E1(145â”162) Hepatitis G Virus Peptide with Phospholipid Membranes. Journal of Physical Chemistry B, 2010, 114, 448-456.	2.6	28

#	Article	IF	Citations
37	Fluorescence study of the dynamic interaction between E1(145â€“162) sequence of hepatitis GB virus C and liposomes. Analytical and Bioanalytical Chemistry, 2009, 394, 1003-1010.	3.7	12
38	Gram-Negative Outer and Inner Membrane Models:Â Insertion of Cyclic Cationic Lipopeptides. Journal of Physical Chemistry B, 2007, 111, 551-563.	2.6	123
39	Influence of lipidation of GBV-C/HGV NS3 (513â€“522) and (505â€“514) peptide sequences on its interaction with mono and bilayers. Colloids and Surfaces B: Biointerfaces, 2007, 57, 8-16.	5.0	8
40	Study of Adsorption and Penetration of E2(279â˜298) Peptide into Langmuir Phospholipid Monolayers. Journal of Physical Chemistry B, 2006, 110, 23292-23299.	2.6	28
41	Analysis of the effect of a peptide sequence of the E2 protein (HGV/GBV-C) on the physicochemical properties of zwitterionic and negatively charged bilayers. Luminescence, 2005, 20, 445-450.	2.9	3
42	Polymyxin B-lipid interactions in Langmuir-Blodgett monolayers ofEscherichia coli lipids: A thermodynamic and atomic force microscopy study. Biopolymers, 2004, 75, 480-490.	2.4	35
43	Interaction of E2 and NS3 synthetic peptides of GB virus C/hepatitis G virus with model lipid membranes. Talanta, 2003, 60, 395-404.	5.5	12
44	Fluorescence analysis of the interaction of two peptide sequences of hepatitis GB virus C with liposomes. Talanta, 2003, 60, 483-491.	5.5	3
45	Peptides and Liposomes: From Biophysical to Immunogenic Studies. Current Drug Targets, 2003, 4, 633-642.	2.1	7
46	Interaction of VP3(110â€“121) Peptide with Hepatocyte and Erythrocyte Membrane Models. Journal of Colloid and Interface Science, 1999, 211, 130-136.	9.4	7
47	Interaction of colistin with lipids in liposomes and monolayers. International Journal of Pharmaceutics, 1998, 160, 99-107.	5.2	24
48	pH-induced destabilization of lipid bilayers by a peptide from the VP3 protein of the capsid of hepatitis A virusâ€. Analyst, The, 1998, 123, 2251-2256.	3.5	12
49	Physicochemical Study of Several Peptide Constructs Based on the Sequence (96â€“107) of VP2-HAV Protein. Journal of Colloid and Interface Science, 1997, 188, 81-93.	9.4	11
50	Theoretical Methods for the Representation of Solvent. Journal of Molecular Modeling, 1996, 2, 1-15.	1.8	61
51	Theoretical representation of solvent effects in the study of biochemical systems. Computational and Theoretical Chemistry, 1996, 371, 269-278.	1.5	14
52	Analysis of the perturbation of phospholipid model membranes by a multiple antigenic peptide. Analytica Chimica Acta, 1995, 303, 57-64.	5.4	7
53	Miscibility of dipalmitoylphosphatidylcholine, oleic acid and cholesterol measured by DSC and compression isotherms of monolayers. Thermochimica Acta, 1994, 232, 261-269.	2.7	8
54	Interaction of Enrofloxacin with Phospholipid Mono- and Bilayers. Langmuir, 1994, 10, 767-772.	3.5	16

#	Article	IF	Citations
55	Interaction of aminoglycosides and colistin with model membranes: Liposomes and monolayers. International Journal of Pharmaceutics, 1993, 90, 59-71.	5.2	29
56	Miscibility of HBV peptides and dipalmitoylphosphatidylcholine in monolayers. Langmuir, 1993, 9, 1129-1133.	3.5	6
57	Synthesis and physicochemical study of collagen hydrophobic derivatives. Langmuir, 1993, 9, 3149-3153.	3.5	8
58	Interaction of Opiate Molecules with Lipid Monolayers and Liposomes. Journal of Pharmaceutical Sciences, 1992, 81, 546-550.	3.3	25
59	Phospholipid-opiate interactions measured by differential scanning calorimetry and compression isotherms of monolayers. Thermochimica Acta, 1991, 185, 99-109.	2.7	1
60	Interactions of naloxone with lipid monolayers. International Journal of Pharmaceutics, 1991, 76, 145-149.	5.2	1
61	A Synthetic Glycopeptide of Substance P Analogue (SP6â€“11) with Enhanced NK-1 Receptor Specificity. Journal of Pharmaceutical Sciences, 1990, 79, 74-76.	3.3	4
62	Preparation andin vitroactivity of liposome encapsulated opioids. Journal of Microencapsulation, 1989, 6, 277-283.	2.8	8
63	Influence of lipid characteristics on the encapsulation efficiency and stability of liposomes. Biochemical Society Transactions, 1989, 17, 1001-1002.	3.4	2
64	Interaction of analgesics with lecithin and ganglioside monolayers. International Journal of Pharmaceutics, 1988, 44, 257-260.	5.2	8